Topic: Staphylococcus aureus

Pfizer has three vaccine programs in development—and top executives have high hopes—but two key programs have competitors close behind.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth. 

Pfizer's Prevnar turned in consensus-beating sales of $1.53 billion in Q4, thanks to government purchases internationally and in the U.S.